Baird raised the firm’s price target on Quest Diagnostics to $138 from $135 and keeps a Neutral rating on the shares. The firm said despite healthy fundamentals, 2024 guidance was below expectations, with 1Q24 expected to be particularly weak. Following disappointing 4Q23 results and 2023 margin walk downs, they need to see more improvement before revisiting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics and Broad Clinical Labs announce collaboration
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024
- Quest Diagnostics management to meet with UBS
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls
- Quest Diagnostics initiated with a Market Perform at Leerink
